The ongoing federal review of the abortion drug mifepristone has become more than a regulatory matter. For Catholics and many others committed to the dignity of human life, it is a test of whether public policy will be guided by truth, prudence, and the duty to protect the most vulnerable.
Originally approved by the U.S. Food and Drug Administration in 2000, mifepristone is now the most common method used in abortions in the United States. Its use has intensified scrutiny, especially after the Dobbs v. Jackson Women’s Health Organization decision returned abortion regulation to the states.
In response, the Trump administration committed the FDA to a new, comprehensive study of the drug’s safety and effectiveness. Initially expected to take about a year, the review has extended beyond that timeline. Officials cite the need for robust data, but the delay raises a practical question: what should be done in the meantime?
Here, the administration’s actions have been notable. Even as the review continues, the Department of Justice has intervened to block or delay efforts by states such as Florida, Indiana, and Texas to restrict mifepristone until the study is complete. The government argues courts should wait for the FDA’s findings. But if credible questions exist about whether a drug is safe for women, should its widespread use continue unchanged during a prolonged review?
This tension becomes clearer when compared to typical drug safety practices. The U.S. Food and Drug Administration has often acted to restrict medications when credible safety concerns arise, even before final conclusions are reached. While not every concern leads to immediate removal, the guiding principle is usually caution. In this case, however, a review is underway precisely because questions remain about safety, yet efforts to limit access are being resisted. This contrast invites reflection on whether the same precaution is being applied consistently.
Catholic teaching approaches this issue from first principles. As the United States Conference of Catholic Bishops has repeatedly affirmed, every human life is sacred from conception to natural death. Abortion, regardless of method, is a grave moral wrong because it intentionally takes innocent human life. At the same time, the Church’s concern extends fully to the well-being of women, insisting that they deserve care that is both life-affirming and genuinely protective of their health.
Several bishops have addressed the rise of chemical abortion. Archbishop Joseph Naumann has warned that abortion pills can further isolate women from needed care. Bishop Michael Burbidge has likewise urged policies that promote a culture of life while simultaneously supporting both mother and child.
A lengthy review may be scientifically prudent. Yet prudence also calls for caution in the face of potential harm. If questions about women’s safety remain unresolved, a more cautious approach would seem consistent with both sound medicine and moral responsibility.
Ultimately, the path forward must defend life, support women, and seek truth with integrity. Every human life deserves protection, and every woman also deserves the care that reflects her full dignity.